B. Pornel

发表

Endometrial safety assessment of a specific and standardized soy extract according to international guidelines

P. Chantre, C. Bergeron, P. Marés, 2007, Menopause.

Tibolone and low‐dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability

E. Nijland, H. Franke, P. V. D. van de Weijer, 2007, BJOG : an international journal of obstetrics and gynaecology.

Efficacy and acceptability of intranasal 17 β-oestradiol for menopausal symptoms: randomised dose-response study

C. Christiansen, J. Bringer, J. Studd, 1999, The Lancet.

A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women

D. Felsenberg, P. Delmas, P. Garnero, 1999 .

Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route.

P. Delmas, P. Lopès, C. Ribot, 2004, Maturitas.

Oral 17&bgr;-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women

O. Chevallier, J. C. Netelenbos, B. Pornel, 2002, Menopause.

Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.

D. Felsenberg, P. Delmas, J. Stakkestad, 2001, American journal of obstetrics and gynecology.

Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.

A. Genazzani, M. Dain, D. Costes, 1995, Maturitas.

Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile.

A. Ferenczy, C. Bergeron, C. Quéreux, 2006, Maturitas.

Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.

J. Studd, M. Birkhäuser, H. Rozenbaum, 1996, Maturitas.

Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.

J. Studd, M. Birkhäuser, H. Rozenbaum, 1996, Maturitas.

Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group.

C. Christiansen, J. Bringer, J. Studd, 1999, Lancet.

Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradio

C. Christiansen, P. Koninckx, S. Rozenberg, 2009, Human reproduction.

A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period

B. Pornel, D. Spielmann, The Trimegestone 302 Study Group, 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Long-term endometrial and breast safety of a specific, standardized soy extract

P. Chantre, P. Marés, S. Palacios, 2010, Climacteric : the journal of the International Menopause Society.

Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women ☆ ☆☆

D. Felsenberg, P. Delmas, J. Stakkestad, 2001 .

EFFICACY AND ACCEPTABILITY OF INTRANASAL 17BETA -OESTRADIOL FOR MENOPAUSALSYMPTOMS : RANDOMISED DOSE-RESPONSE STUDY

C. Christiansen, J. Bringer, J. Studd, 1999 .

Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate

F. al-Azzawi, J. Thompson, O. Ylikorkala, 2001, Climacteric : the journal of the International Menopause Society.